Lakefront Biotherapeutics (LKFT) Depreciation & Amortization (CF) (2016 - 2020)

Lakefront Biotherapeutics (LKFT) has reported Depreciation & Amortization (CF) for 5 consecutive years, with $4.6 million the latest figure, recorded in Q1 2020.

• In Q1 2020, Depreciation & Amortization (CF) rose 47.52% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $0.0 (changed 0.0% YoY), while the FY2017 annual figure was $4.3 million, up 16.31% from the prior year.
• Depreciation & Amortization (CF) advanced to $4.6 million in Q1 2020 per LKFT's latest filing, from $3.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.2 billion in Q2 2018 and bottomed at -$2.2 billion in Q3 2018.
• Historically, Depreciation & Amortization (CF) has averaged -$5.5 million across 5 years, with a median of $1.0 million in 2017.
• Annual changes were most pronounced in 2017 — Depreciation & Amortization (CF) soared 211301.51% — and 2018, when it decreased 3.77%.
• Lakefront Biotherapeutics' Depreciation & Amortization (CF) stood at $925367.6 in 2016, then rose by 10.7% to $1.0 million in 2017, then slumped by 211654.43% to -$2.2 billion in 2018, then soared by 100.14% to $3.1 million in 2019, then surged by 47.52% to $4.6 million in 2020.
• Business Quant data shows LKFT's Depreciation & Amortization (CF) at $4.6 million in Q1 2020, $3.1 million in Q1 2019, and -$2.2 billion in Q3 2018.